Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ISRCTN11919759
ISRCTN11919759Active, not recruitingUnknown

Hepatitis A vaccination coverage amongst people with Chronic Liver Disease in England (HEALD): protocol for a retrospective cohort sentinel network database study

niversity of Oxford0 sites1,650 target enrollmentStarted: October 12, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Unknown
Status
Active, not recruiting
Enrollment
1,650
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •We will include adults registered in general practices within the RSC network, with a diagnosis of CLD, as defined by our ontology, within the period between the 1st January 2012 and 31st December 2022. The following inclusion criteria will be applied:
  • •People registered in the RSC general practices, aged 18 years of age and older, with a diagnosis of CLD. Our ontology for CLD includes: Alcoholic liver disease (ALD), chronic hepatitis B (CH-B), chronic hepatitis C (CH-C), non-alcoholic fatty liver disease, Wilson´s Disease, haemochromatosis, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Exclusion Criteria

  • •1. Patients with recorded contraindications to the Hep A vaccine (confirmed anaphylactic reaction to a previous dose of Hep A containing vaccine, or to any of its components).
  • •2. Records of administration of post-infection or risk-of-infection immunoglobulins.

Investigators

Similar Trials

Not yet recruiting
Not Applicable
To find out prior infection of Hepatitis A in non vaccinated adolescents aged 9-12 years
CTRI/2022/10/046790Department of Pediatrics
Completed
Not Applicable
To assess the presence of antibodies against Hepatitis A in children and adults from four cities of India.
CTRI/2019/11/022007Bharati Vidyapeeth Deemed to be University Medical College Hospital2,230
Active, not recruiting
Not Applicable
Hepatitis A vaccine in patients with immunomodulative drugsPatients with rheumatoid arthritis treated with immunosuppressive medicationMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisMedDRA version: 12.1Level: LLTClassification code 10054980Term: Immunosuppressant drug therapyMedDRA version: 12.1Level: LLTClassification code 10063430Term: Hepatitis A immunisation
EUCTR2009-016055-22-SEHY, HUS380
Active, not recruiting
Phase 1
Hepatitis vaccination til patienter med HIV infektion. Betydning af adjuverende interleukin-2Patienter med Hiv infektion har øget risiko for hepatitis A og hepatitis B. Sundhedsmyndigheder anbefaler vaccination. Effekt er imidlertid mindre end for raske personer. Forsøget tester om adjuverende interleukin-2 øger effekt.
EUCTR2005-002171-33-DKAalborg Sygehus Syd50
Not yet recruiting
Not Applicable
BEe-HIVe-Z21 Asymptomatic human immunodeficiency virus [HIV] infection statusAsymptomatic human immunodeficiency virus [HIV] infection statusZ21
PER-061-20El Instituto Nacional de Alergia y Enfermedades Infecciosas (NIAID) de los Estados Unidos,